KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Payables (2016 - 2026)

NovoCure's Payables history spans 13 years, with the latest figure at $127.2 million for Q1 2026.

  • On a quarterly basis, Payables fell 80.55% to $127.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $127.2 million, a 80.55% decrease, with the full-year FY2025 number at $122.2 million, down 81.57% from a year prior.
  • Payables hit $127.2 million in Q1 2026 for NovoCure, up from $122.2 million in the prior quarter.
  • Over the last five years, Payables for NVCR hit a ceiling of $679.5 million in Q3 2025 and a floor of $69.2 million in Q1 2022.
  • Historically, Payables has averaged $257.8 million across 5 years, with a median of $90.2 million in 2024.
  • Biggest five-year swings in Payables: skyrocketed 714.19% in 2024 and later tumbled 81.57% in 2025.
  • Tracing NVCR's Payables over 5 years: stood at $85.2 million in 2022, then grew by 10.79% to $94.4 million in 2023, then soared by 602.66% to $663.2 million in 2024, then tumbled by 81.57% to $122.2 million in 2025, then increased by 4.1% to $127.2 million in 2026.
  • Business Quant data shows Payables for NVCR at $127.2 million in Q1 2026, $122.2 million in Q4 2025, and $679.5 million in Q3 2025.